Abstract：
UNASSIGNED: Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients.
UNASSIGNED: Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis.
UNASSIGNED: Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), p = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), p = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), p = 0.05].
UNASSIGNED: Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events.
UNASSIGNED: PROSPERO (No. CRD42023466988).
UNASSIGNED: Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis.
UNASSIGNED: Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), p = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), p = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), p = 0.05].
UNASSIGNED: Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events.
UNASSIGNED: PROSPERO (No. CRD42023466988).
摘要：
■由于其抗血管生成特性，trebanib经常用于治疗癌症患者，尤其是卵巢癌患者。我们进行了一项荟萃分析，以评估曲巴那尼与其他药物联合治疗卵巢癌和非卵巢癌患者的疗效和安全性。
■我们的搜索包括PubMed，Medline,科克伦,和Embase数据库，重点评估研究质量。数据提取来自随机对照试验(RCTs)，和RevMan5.3促进了结果分析。
■将曲巴纳尼与其他药物联合使用可延长无进展生存期（PFS）[HR0.81，（95CI：0.65，0.99），p=0.04]和总生存率（OS）[HR0.88，（95CI：0.79，1.00），在卵巢癌患者中p=0.04。与非卵巢癌队列相比，卵巢癌患者使用trebanib表现出更高的客观反应率（ORR）。此外，在恶性肿瘤的标准治疗方案中加入曲巴那尼并没有显著增加药物相关的不良事件[RR1.05,(95%CI:1.00,1.11),p=0.05]。
■Trebanib加上其他药物可以改善PFS，癌症患者的OS和ORR，尤其是卵巢癌.我们的建议是使用trebanib和其他药物来治疗晚期癌症，并持续监测和管理与药物相关的不良事件。
■PROSPERO（编号：CRD42023466988)。
■我们的搜索包括PubMed，Medline,科克伦,和Embase数据库，重点评估研究质量。数据提取来自随机对照试验(RCTs)，和RevMan5.3促进了结果分析。
■将曲巴纳尼与其他药物联合使用可延长无进展生存期（PFS）[HR0.81，（95CI：0.65，0.99），p=0.04]和总生存率（OS）[HR0.88，（95CI：0.79，1.00），在卵巢癌患者中p=0.04。与非卵巢癌队列相比，卵巢癌患者使用trebanib表现出更高的客观反应率（ORR）。此外，在恶性肿瘤的标准治疗方案中加入曲巴那尼并没有显著增加药物相关的不良事件[RR1.05,(95%CI:1.00,1.11),p=0.05]。
■Trebanib加上其他药物可以改善PFS，癌症患者的OS和ORR，尤其是卵巢癌.我们的建议是使用trebanib和其他药物来治疗晚期癌症，并持续监测和管理与药物相关的不良事件。
■PROSPERO（编号：CRD42023466988)。
